REFERENCES
- Bartlett JG. Ten years of HAART: Foundation for the future. Medscape website. 2006. Available at: http://www.medscape.org/viewarticle/523119. Accessed June 10, 2015.
- Ng P, McCluskey P, McCaughan G, et al. Ocular complications of heart, lung, and liver transplantation. Br J Ophthalmol. 1998;82(4):423–428.
- Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002; 1,35(7):866–872.
- Chou S, Lurain NS, Thompson KD, et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis. 2003;188(1):32–39.
- Jabs DA, Enger C, Dunn JP, et al. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis. 1998;177(3):770–773.
- Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42(9):2240–2244.
- Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 2004;34(12):1071–1075.
- Breedveld F, Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59(11): 841–849.
- Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 1999;42:412–418.
- Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–426.
- Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2010;2(5):637–650.
- Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci. 2002;323(4):190–193.
- Harvala H, Stewart C, Muller K, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85(5):893–898.
- Patel M, Coombs P, Prockop S, et al. Treatment of cytomegalovirus (CMV) retinitis with CMV-specific T-lymphocyte infusion. Ophthalmic Surg Lasers Imaging Retina. 2015;46:80–82.
- Kujawski J, Bernard MK, Jodlowska E, et al. On the interactions of leflunomide and teriflunomide within receptor cavity – NMR studies and energy calculations. J Mol Model. 2015;21(5):105.
- Chacko B, John GT. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis. 2012;14(22): 111–120.
- Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22(2):162–170.
- Chon WJ, Kadambi PV, Xu C, et al. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the university of Chicago. Case Rep Nephrol Dial. 2015;5(1):96–105.
- Dunn JH, Weinberg A, Chan LK, et al. Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. JAMA Ophthalmol. 2013;131(7):958–960.